Estimating Cost Savings from Early Cancer Diagnosis

Zura Kakushadze, Rakesh Raghubanshi and Willie Yu
Additional contact information
Zura Kakushadze: Quantigic ® Solutions LLC, 1127 High Ridge Road, #135, Stamford, CT 06905, USA
Rakesh Raghubanshi: Two29 Consulting LLC, 46 Sewell Avenue, Piscataway, NJ 08854, USA
Willie Yu: Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore

Data, 2017, vol. 2, issue 3, 1-16

Abstract: We estimate treatment cost-savings from early cancer diagnosis. For breast, lung, prostate and colorectal cancers and melanoma, which account for more than 50% of new incidences projected in 2017, we combine published cancer treatment cost estimates by stage with incidence rates by stage at diagnosis. We extrapolate to other cancer sites by using estimated national expenditures and incidence rates. A rough estimate for the U.S. national annual treatment cost-savings from early cancer diagnosis is in 11 digits. Using this estimate and cost-neutrality, we also estimate a rough upper bound on the cost of a routine early cancer screening test.

Keywords: cancer; costs; incidence; stage; early diagnosis; treatment; data (search for similar items in EconPapers)
JEL-codes: C8 C80 C81 C82 C83 (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.mdpi.com/2306-5729/2/3/30/pdf (application/pdf)
https://www.mdpi.com/2306-5729/2/3/30/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jdataj:v:2:y:2017:i:3:p:30-:d:110841

Access Statistics for this article

Data is currently edited by Ms. Cecilia Yang

More articles in Data from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().